Document Detail


Pulmonary Vasodilation in Acute and Chronic Heart Failure: Empiricism and Evidence.
MedLine Citation:
PMID:  21556702     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Pulmonary hypertension in heart failure is associated with exercise intolerance and adverse outcomes. With the availability of multiple drugs that cause pulmonary vasodilation and decrease pulmonary arterial pressure, pulmonary hypertension becomes an attractive therapeutic target. Out of several classes of medications, oral phosphodiesterase inhibitors emerge as the most promising in terms of symptomatic improvement, hemodynamic benefits, reverse cardiac remodeling, and functional capacity. Future trials will show whether the use of these drugs translates to decreased morbidity and mortality in heart failure.
Authors:
Maya Guglin
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-10
Journal Detail:
Title:  Current heart failure reports     Volume:  -     ISSN:  1546-9549     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101196487     Medline TA:  Curr Heart Fail Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Cardiology, University of South Florida, 2A Columbia Drive, Suite 5074, Tampa, FL, 33618, USA, mguglin@health.usf.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic analysis and QTL detection of reproductive period and post-flowering photoperiod responses i...
Next Document:  The Value of Data Collection within a Palliative Care Program.